What are the benefits of taking vascepa long term?

What side effects might build up over years of use?

Long-term Vascepa use appears well tolerated in studies extending beyond four years. Cardiovascular event reduction persisted through 4.9 years of follow-up in the REDUCE-IT trial, and serious adverse events remained comparable to placebo. Triglyceride reductions held steady once established, so no dose adjustment is needed for maintenance.

How does Vascepa affect inflammation markers over time?

Omega-3 fatty acid EPA in Vascepa lowers inflammatory markers such as hs-CRP and oxidized LDL. These changes appeared early in the trial and stayed consistent throughout the study period, helping explain the observed cardiovascular risk reduction.

When does Vascepa patent protection end?

Vascepa’s composition-of-matter patent expired in 2020. Composition-of-matter patent protection for icosapent ethyl ended in 2020. Generic versions entered the market in 2021 after settlement agreements with Amarin. Generic availability lowered monthly costs from roughly $300 to under $100 for most patients.

What happens if you stop taking Vascepa?

Trial data show cardiovascular benefit requires continued treatment. Patients who discontinued early showed rapid rebound in triglyceride levels and increased risk of ischemic events. Persistent use keeps both triglyceride suppression and event-rate reduction active.

How competitive is the icosapent ethyl space?

Several generics manufacturers now supply icosapent ethyl. Amarin continues marketing branded Vascepa through its remaining method-of-use patents, but these rights end in 2030 at the latest.